This update from the U.S. Food and Drug Administration (FDA) is not an announcement of new drug approvals or a simultaneous label revision for 200 products. Instead, it is an ongoing, updated table that compiles pharmacogenomic (PGx) biomarker information from labels of already-approved drugs. The FDA includes information related to identifying responsive patients, avoiding adverse reactions, establishing genotype-specific dosages, and addressing differences in drug exposure. Some products specifically require biomarker-based prescribing instructions. Therefore, this should be interpreted as a regulatory infrastructure update that demonstrates the clinical utility and diagnostic demand of existing labels, rather than a direct catalyst for increased sales.

Plavix (clopidogrel), a marketed antiplatelet agent from Bristol Myers Squibb (BMY) and Sanofi (SNY), inhibits platelet P2Y12 receptors, but requires CYP2C19 for the generation of its active metabolite. On March 12, 2010, the FDA approved a boxed warning stating that in CYP2C19 poor metabolizers, the drug's efficacy is reduced, and the risk of cardiovascular events increases. The current table links CYP2C19 with the boxed warning, precautions, and clinical pharmacology sections. In comparison, AstraZeneca's (AZN) Brilinta (ticagrelor) and Daiichi Sankyo (4568.T) and Eli Lilly's (LLY) Effient (prasugrel), which are competing standard treatments, do not depend on CYP2C19 activation, leading to ongoing competition in prescribing that considers both genotype and the risk of bleeding.

Ziagen (abacavir), a marketed HIV treatment from GlaxoSmithKline (GSK), is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase and received FDA approval on December 19, 1998. Individuals with the HLA-B*5701 allele are at higher risk of severe and life-threatening hypersensitivity reactions. The FDA label requires testing before administration and prohibits use in positive patients. This contrasts with integrase inhibitor-based standard therapies such as Gilead Sciences' (GILD) Biktarvy or GSK's Dovato, demonstrating that biomarkers can determine not only drug efficacy but also prescription exclusion criteria and the cost of safety management.

Herceptin (trastuzumab), a marketed HER2 antibody from Roche's (RHHBY) subsidiary, Genentech, targets ERBB2/HER2 receptors. The FDA and HercepTest were both approved on September 25, 1998. Currently, in HER2-positive breast cancer, Daiichi Sankyo and AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki), Roche's Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine), and trastuzumab biosimilars compete for patient populations and treatment lines. The global companion diagnostics (CDx) market is projected to reach $9.6 billion in 2025 and $10.3 billion in 2026, demonstrating a structure in which the expansion of biomarker labels is linked to increased testing volume and the demand for co-development between pharmaceutical and diagnostic companies.

Vrtx (VRTX), a marketed cystic fibrosis treatment from Vertex Pharmaceuticals, is a CFTR chloride channel enhancer and was the first genotype-based treatment approved by the FDA on January 31, 2012, for patients with the G551D mutation. This table update does not involve separate advisory committee (AdComm) votes or new Phase 1, 2, or 3 clinical trial results, so the approval stage and prescribing information for each product should be checked separately. From an investment perspective, the direct benefits are more focused on companies with FDA-approved tests, tissue/liquid biopsies, next-generation sequencing (NGS), and companion diagnostic portfolios linked to pharmaceutical companies, rather than companies that simply possess genomic data.